Aligos Therapeutics (ALGS) Change in Cash (2019 - 2026)
Aligos Therapeutics' (ALGS) quarterly Change in Cash came in at $11.7 million in Q1 2026, down 68.07% YoY from $36.8 million in Q1 2025, and up 149.66% on a QoQ basis from -$23.6 million in Q4 2025.
Aligos Therapeutics (ALGS) Change in Cash (2019 - 2026) Analysis & Trends
Aligos Therapeutics (ALGS) has 8 years of Change in Cash data on file, last reported at $11.7 million in Q1 2026.
- Quarterly Change in Cash fell 68.07% year-over-year to $11.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$43.7 million (down 188.31% YoY) and the FY2025 annual result came in at -$18.7 million, up 81.05% from the prior year.
- Change in Cash advanced to $11.7 million in Q1 2026, from -$23.6 million in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $65.3 million in Q4 2023 to a low of -$111.4 million in Q1 2024.
- A 5-year average of -$9.2 million and a median of -$2.4 million in 2023 frame the typical range for Change in Cash.
- Annual changes were most pronounced in 2023 — Change in Cash jumped 1390.45% — and 2024, when it tumbled 4551.65%.
- Tracing ALGS's Change in Cash over 5 years: stood at -$5.1 million in 2022, then jumped by 1390.45% to $65.3 million in 2023, then sank by 97.45% to $1.7 million in 2024, then sank by 1519.15% to -$23.6 million in 2025, then jumped by 149.66% to $11.7 million in 2026.
- The last three Change in Cash figures came in at $11.7 million (Q1 2026), -$23.6 million (Q4 2025), and $23.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 649.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.60 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -185.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 427.25 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.94 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.42 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | Aligos Therapeutics | 68.90 Mn | 38.45 Mn | - | 269,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 269,000.00 |
| Mar 31, 2026 | 11.74 Mn |
| Dec 31, 2025 | -23.64 Mn |
| Sep 30, 2025 | 23.29 Mn |
| Jun 30, 2025 | -55.10 Mn |
| Mar 31, 2025 | 36.77 Mn |
| Dec 31, 2024 | 1.67 Mn |
| Sep 30, 2024 | -9.71 Mn |
| Jun 30, 2024 | 20.78 Mn |
| Mar 31, 2024 | -111.41 Mn |
| Dec 31, 2023 | 65.27 Mn |
| Sep 30, 2023 | -20.37 Mn |
| Jun 30, 2023 | 11.80 Mn |
| Mar 31, 2023 | -2.40 Mn |
| Dec 31, 2022 | -5.06 Mn |
| Sep 30, 2022 | 15.33 Mn |
| Jun 30, 2022 | -34.93 Mn |
| Mar 31, 2022 | -80.86 Mn |
| Dec 31, 2021 | -53.41 Mn |
| Sep 30, 2021 | 52.54 Mn |